Oral ketamine — Competitive Intelligence Brief

Oral ketamine (Oral ketamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist. Area: Psychiatry, Pain Management, Anesthesia.

marketed NMDA receptor antagonist NMDA receptor Psychiatry, Pain Management, Anesthesia Small molecule

Target snapshot

Oral ketamine (Oral ketamine) — Universidade Federal de Goias. Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks glutamate signaling in the central nervous system.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral ketamine TARGET	Oral ketamine	Universidade Federal de Goias	marketed	NMDA receptor antagonist	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
Intranasal dexmedetomidine-esketamine	Intranasal dexmedetomidine-esketamine	Peking University First Hospital	marketed	Alpha-2 adrenergic agonist / NMDA receptor antagonist combination	Alpha-2 adrenergic receptors; NMDA receptor
Sevoflurane Inhalation Liquid	Sevoflurane Inhalation Liquid	Damanhour Teaching Hospital	marketed	Volatile general anesthetic	GABA-A receptor, NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist class)

1. Turku University Hospital · 3 drugs in this class
2. H. Lundbeck A/S · 2 drugs in this class
3. Ciusss de L'Est de l'Île de Montréal · 2 drugs in this class
4. Shalvata Mental Health Center · 2 drugs in this class
5. New York State Psychiatric Institute · 2 drugs in this class
6. Auris Medical AG · 1 drug in this class
7. AstraZeneca · 1 drug in this class
8. Alameda Health System · 1 drug in this class
9. Centre Hospitalier Universitaire de Nice · 1 drug in this class
10. Asker & Baerum Hospital · 1 drug in this class